RT Journal Article
SR Electronic
T1 Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 1273
OP 1281
DO 10.1212/WNL.0000000000003770
VO 88
IS 13
A1 Day, Gregory S.
A1 Lim, Tae Sung
A1 Hassenstab, Jason
A1 Goate, Alison M.
A1 Grant, Elizabeth A.
A1 Roe, Catherine M.
A1 Cairns, Nigel J.
A1 Morris, John C.
YR 2017
UL http://n.neurology.org/content/88/13/1273.abstract
AB Objective: To identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD).Methods: Clinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing.Results: Substantial overlap was observed between individuals with dementia due to CBD and AD concerning presenting complaints, median (range) duration of symptoms before assessment (CBD = 3.0 [0–5.0] years, AD = 2.5 [0–8.0] years; p = 0.96), and median (range) baseline dementia severity (Clinical Dementia Rating Sum of Boxes: CBD = 3.5 [0–12.0], AD = 4.25 [0.5–9.0], p = 0.49). Subsequent emergence of asymmetric motor/sensory signs, hyperreflexia, gait abnormalities, parkinsonism, falls, urinary incontinence, and extraocular movement abnormalities identified individuals with CBD, with ≥3 discriminating features detected in 80% of individuals within 3.1 years (95% confidence interval 2.9–3.3) of the initial assessment. Individuals with CBD exhibited accelerated worsening of illness severity and declines in episodic memory, executive functioning, and letter fluency. Semiquantitative pathologic assessment revealed prominent tau pathology within the frontal and parietal lobes of CBD cases. Comorbid AD neuropathologic change was present in 59% (10 of 17) of CBD cases but did not associate with the clinical phenotype, rate of dementia progression, or dementia duration.Conclusions: CBD may mimic AD dementia early in its disease course. Interval screening for discriminating clinical features may improve antemortem diagnosis in individuals with CBD and prominent cognitive symptoms.AD=Alzheimer disease; ADNC=Alzheimer disease neuropathologic change; ADRC=Alzheimer Disease Research Center; bvFTD=behavioral-variant frontotemporal dementia; CBD=corticobasal degeneration; CBS=corticobasal syndrome; CDR=Clinical Dementia Rating; CI=confidence interval; MAPT=microtubule-associated protein tau; MDC=Memory Diagnostic Center; SB=Sum of Boxes; TDP-43=TAR DNA-binding protein of 43 kDa